Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France

The 55,000-Square-Foot Facility is the Latest Addition to Cryoport Systems' Global Supply Chain Center Network

Designed to Support Complex Life Sciences Supply Chain Needs, Including Biologistics, BioServices and Future Cryopreservation Services Worldwide

NASHVILLE, Tenn., Oct. 1, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of its newest, state-of-the art facility in Louvres, France, through its subsidiary, Cryoport Systems. The facility, which is strategically located near the Paris Charles de Gaulle Airport, marks a strategic expansion of Cryoport Systems' Global Supply Chain Center (GSCC) network, which offers end-to-end temperature-controlled supply chain solutions and capabilities.

Purpose-built to streamline operations and address critical challenges in the advanced therapies market, the facility provides end-to-end, temperature-controlled supply chain solutions under one roof. As the third global supply chain center campus in Cryoport's network, it will offer global accessibility for biopharma and other temperature-sensitive commodities.

The facility will be immediately operational, providing logistics support for biopharma, including cell and gene therapies, biologics, animal health and reproductive medicine. During the months following, the Paris GSCC will add BioServices, biostorage, QP drug management, Importer of Record (IOR) services and additional offerings from Cryoport Systems' suite of services. This phased, integrated approach will support both clinical and commercial cell and gene therapy programs.

"Our new facility in Louvres strengthens Cryoport Systems' Global Supply Chain Center Network significantly and provides us with increased ability to serve our clients in the European and global markets," said Jerrell Shelton, CEO of Cryoport. "By providing integrated capabilities and end-to-end services, we will continue to ensure secure, compliant handling of temperature-sensitive commodities and help our clients to deliver therapies safely and efficiently to patients in need."

With today's launch of logistical operations, the facility will offer 24-hour worldwide dispatch capabilities from order receipt to deployment of Cryoport's wholly owned fleet of proprietary shipping systems. It will also offer the same demanding quality oversight in full alignment with Cryoport Systems' GSCC network. The Paris GSCC was funded, in part, by a grant provided to Cryoport Systems by the Île-de-France region to support initial operations as a way of promoting economic growth within the area.

An official grand opening to celebrate the launch of the Paris GSCC will be held on November 20, 2025, bringing together local dignitaries, distinguished members of Île-de-France and market leaders in the European advanced therapies space.

About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a leading global provider of temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the Life Sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.

Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

SOURCE Cryoport, Inc.